Table 1 Characteristics of included BC patients with different AR expression statuses
Characteristics | AR- (n = 15) | AR+ (n = 33) | t/x2/z | p-value |
|---|---|---|---|---|
Age (years) | 56.00 ± 15.28 | 53.70 ± 13.74 | 0.520 | 0.606 |
BMI (kg/m2) | 24.69 ± 4.25 | 24.82 ± 4.02 | 0.100 | 0.921 |
Menopausal Status | 0.162 | 0.688 | ||
Premenopausal | 5(33.3%) | 13(39.4%) | ||
Postmenopausal | 10(66.7%) | 20(60.6%) | ||
Tumor Location | 0.014 | 0.907 | ||
Left | 8(53.3%) | 17(51.5%) | ||
Right | 7(46.7%) | 16(48.5%) | ||
Histologic Type | 0.514 | 0.662 | ||
IDC | 12(80.0%) | 29(87.9%) | ||
Other | 3(20.0%) | 4(12.1%) | ||
Clinical Stage | 0.730 | 0.393 | ||
I-II | 4(26.7%) | 13(39.4%) | ||
III-IV | 11(73.3%) | 20(60.6%) | ||
Clinical T Stage | 0.183 | 0.738 | ||
T1-T2 | 10(66.7%) | 24(72.7%) | ||
T3-T4 | 5(33.3%) | 9(27.3%) | ||
Clinical N Stage | 1.302 | 0.629 | ||
N0 | 4(26.7%) | 14(42.4%) | ||
N1-2 | 6(40.0%) | 9(27.3%) | ||
N3 | 5(33.3%) | 10(30.3%) | ||
Clinical M Stage | 0.032 | 1.000 | ||
M0 | 11(73.3%) | 25(75.8%) | ||
M1 | 4(26.7%) | 8(24.2%) | ||
ER Status | 2.334 | 0.127 | ||
Positive | 7(46.7%) | 23(69.7%) | ||
Negative | 8(53.3%) | 10(30.3%) | ||
PR Status | 3.499 | 0.061 | ||
Positive | 3(20.0%) | 16(48.5%) | ||
Negative | 12(80.0%) | 17(51.5%) | ||
HER2 Status | 0.162 | 0.688 | ||
Positive | 5(33.3%) | 13(39.4%) | ||
Negative | 10(66.7%) | 20(60.6%) | ||
Molecular Subtype | 3.232 | 0.337 | ||
HR+/HER2- | 6(40.0%) | 15(45.5%) | ||
HR+/HER2+ | 1(6.7%) | 8(24.2%) | ||
HER2+ | 4(26.7%) | 5(15.2%) | ||
TNBC | 4(26.7%) | 5(15.2%) | ||
Ki-67 | 0.041 | 0.839 | ||
<30% | 5(33.3%) | 12(36.4%) | ||
≥30% | 10(66.7%) | 21(63.6%) | ||
SUVmax | 8.38 ± 6.61 | 7.70 ± 4.49 | 0.416 | 0.679 |
SUVmean | 2.66 ± 2.02 | 2,94 ± 1.91 | -0.477 | 0.636 |
TLG* | 62.00(19.11 ~ 126.26) | 44.26(15.62 ~ 129.46) | -0.612 | 0.541 |
MTV* | 35.50(20.83 ~ 64.00) | 17.70 (8.70 ~ 47.53) | -2.146 | 0.032 |